SPL
LIVE

Serial Number

97898955

Owner

Hepalink USA Inc.

Attorney

Gordon M. Wright

First Use Date

Jan 1, 1976

Filing Date

Apr 20, 2023

Add to watchlist:

No watchlists yet
View on USPTO

SPL Trademark

Serial Number: 97898955 • Registration: 7355282

SPL is a trademark filed by Hepalink USA Inc. on April 20, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Hepalink USA Inc. (7 trademarks)

2005 Cabot Boulevard West, Suite 200
Langhorne, PA 190471885

Entity Type: 03

Trademark Details

Filing Date

April 20, 2023

Registration Date

April 9, 2024

First Use Anywhere

January 1, 1976

First Use in Commerce

January 1, 1976

Published for Opposition

January 23, 2024

Goods & Services

Manufacturing services for others in a cGMP ("Current Good Manufacturing Practice") compliant facility in the field of therapeutic compounds, namely, the extraction, isolation and purification of naturally derived and fermentation-derived therapeutic compounds

Pharmaceutical products and preparations containing active pharmaceutical ingredients, namely, pharmaceutical grade Heparin Sodium, pharmaceutical grade Pancreatin, and pharmaceutical grade Pancrealipase, for use in humans for the prevention and treatment of thrombotic events and to treat pancreatic insufficiency and related diseases; Pharmaceutical products and preparations, namely, anticoagulants; pharmaceutical products and preparations for the testing, sampling and identification of viruses, namely, medical diagnostic reagents and assays for testing of body fluids; Chemical preparations for sanitary use; Chemical preparations for treating mildew; Diagnostic preparations for medical purposes; Injectable pharmaceuticals for treatment of anaphylactic reactions; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for treating thyroid conditions; Pharmaceutical preparations for wounds; Diagnostic preparations for use with medical devices; Pharmaceutical preparations for treating thrombotic events and pancreatic insufficiency for use with medical devices for drug delivery; Pharmaceutical preparations for ophthalmological use, namely, for treating eye diseases and disorders; none of the foregoing for use with animals

Pharmaceutical contract development in a cGMP ("Current Good Manufacturing Practice") compliant facility in the field of therapeutic compounds, namely, the extraction, isolation and purification of naturally derived and fermentation-derived therapeutic compounds

Filing History

REGISTERED-PRINCIPAL REGISTER
Apr 9, 2024 R.PR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Apr 9, 2024 NRCC
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 23, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jan 23, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 3, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 14, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
Dec 12, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Dec 12, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
Dec 12, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
Dec 12, 2023 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 4, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 3, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 3, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 7, 2023 GNRN
NON-FINAL ACTION E-MAILED
Aug 7, 2023 GNRT
NON-FINAL ACTION WRITTEN
Aug 7, 2023 CNRT
ASSIGNED TO EXAMINER
Jul 28, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 17, 2023 NWOS
NEW APPLICATION ENTERED
Apr 24, 2023 NWAP